Savara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP

Reuters

10/15

<a href="https://laohu8.com/S/SVRA">Savara Inc</a>. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP

Savara Inc. has released a corporate presentation detailing its ongoing development of new therapies for rare respiratory diseases. The presentation highlights MOLBREEVI (molgramostim inhalation solution), which recently demonstrated clinically meaningful positive Phase 3 results in patients with autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The results suggest that MOLBREEVI may address the underlying pathophysiology of autoimmune PAP, showing a favorable benefit-risk profile and being well tolerated in clinical trials. The company plans to resubmit its Biologics License Application (BLA) in December 2025. The presentation also provides an overview of the disease burden of autoimmune PAP and the current and potential future patient journeys. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575392244"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575392244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575392244?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 03:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575392244","market":"fut","top_or_hot":-1,"title":"Savara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SVRA\">Savara Inc</a>. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Savara Inc. has released a corporate presentation detailing its ongoing development of new therapies for rare respiratory diseases. The presentation highlights MOLBREEVI (molgramostim inhalation solution), which recently demonstrated clinically meaningful positive Phase 3 results in patients with autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The results suggest that MOLBREEVI may address the underlying pathophysiology of autoimmune PAP, showing a favorable benefit-risk profile and being well tolerated in clinical trials. The company plans to resubmit its Biologics License Application (BLA) in December 2025. The presentation also provides an overview of the disease burden of autoimmune PAP and the current and potential future patient journeys. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Savara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSavara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-15 03:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SVRA\">Savara Inc</a>. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Savara Inc. has released a corporate presentation detailing its ongoing development of new therapies for rare respiratory diseases. The presentation highlights MOLBREEVI (molgramostim inhalation solution), which recently demonstrated clinically meaningful positive Phase 3 results in patients with autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The results suggest that MOLBREEVI may address the underlying pathophysiology of autoimmune PAP, showing a favorable benefit-risk profile and being well tolerated in clinical trials. The company plans to resubmit its Biologics License Application (BLA) in December 2025. The presentation also provides an overview of the disease burden of autoimmune PAP and the current and potential future patient journeys. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SVRA","symbol_name":"Savara Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL3WgbQR:1","article_id":"2575392244","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575392244","pubTimestamp":1760471272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Savara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP. Savara Inc. has released a corporate presentation detailing its ongoing development of new therapies for rare respiratory diseases. The presentation highlights MOLBREEVI , which recently demonstrated clinically meaningful positive Phase 3 results in patients with autoimmune pulmonary alveolar proteinosis . The results suggest that MOLBREEVI may address the underlying pathophysiology of autoimmune PAP, showing a favorable benefit-risk profile and being well tolerated in clinical trials. The company plans to resubmit its Biologics License Application  in December 2025. The presentation also provides an overview of the disease burden of autoimmune PAP and the current and potential future patient journeys. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellig","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SVRA":"Savara Inc","BK4139":"生物科技"},"translate_title":"Savara Inc.发布公司演示文稿，重点介绍MOLBREEVI治疗罕见呼吸道疾病自身免疫性PAP的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SVRA":0.9},"content_text":"Savara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP\n    \n\n        Savara Inc. has released a corporate presentation detailing its ongoing development of new therapies for rare respiratory diseases. The presentation highlights MOLBREEVI (molgramostim inhalation solution), which recently demonstrated clinically meaningful positive Phase 3 results in patients with autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The results suggest that MOLBREEVI may address the underlying pathophysiology of autoimmune PAP, showing a favorable benefit-risk profile and being well tolerated in clinical trials. The company plans to resubmit its Biologics License Application (BLA) in December 2025. The presentation also provides an overview of the disease burden of autoimmune PAP and the current and potential future patient journeys. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}